Page last updated: 2024-09-03

imatinib mesylate and Neoplasm Metastasis

imatinib mesylate has been researched along with Neoplasm Metastasis in 165 studies

Research

Studies (165)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	71 (43.03)	29.6817
2010's	88 (53.33)	24.3611
2020's	6 (3.64)	2.80

Authors

Authors	Studies
Doi, T; Komatsu, Y; Kurokawa, Y; Naito, Y; Nishida, T; Ohkubo, S; Ozaka, M; Sawaki, A; Takahashi, T	1
Blay, JY; Bompas, E; Brahmi, M; Cassier, PA; Desai, J; Eberst, L; Gelderblom, H; Hannink, G; Italiano, A; Maki, RG; Mastboom, MJL; Mir, O; Seddon, BM; Stacchiotti, S; van de Sande, MAJ; van der Graaf, WTA; Verspoor, FGM; Wagner, A	1
Abdou, Y; Ernstoff, MS; Hamad, L; Kapoor, A	1
Aickara, DJ; McBride, J; Morrison, B; Romanelli, P	1
ElShamy, WM; Koziol, J; Ryan, D	1
Cai, Z; Fu, W; Pu, L; Shen, C; Wang, J; Wang, Y; Yin, X; Yin, Y; Zhang, B	1
Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z	1
Banerjee, S; Kumar, A; Lopez, N; Murphy, JD; Sicklick, JK; Tang, CM; Yebra, M; Yoon, H; Zhao, B	1
Kim, BJ; Kim, HJ; Kim, HS; Kim, JG; Park, JM; Park, JY	1
Chi, P; Gutierrez Sainz, L; Kelly, CM	1
Baia, M; Bastiaannet, E; Desar, IME; Farag, S; Gelderblom, H; Gronchi, A; Hohenberger, P; IJzerman, NS; Jones, RL; Martin-Broto, J; Mohammadi, M; Oosten, AW; Reyners, AKL; Rutkowski, P; Schöffski, P; Schrage, Y; Steeghs, N; van Sandick, JW; Vassos, N	1
Kubo, N; Takeuchi, N	1
Blay, JY; Casali, PG; Fumagalli, E; Gronchi, A; Grünwald, V; Hogendoorn, P; Italiano, A; Judson, IR; Kerst, JM; Kotasek, D; Le Cesne, A; Leyvraz, S; Lindner, LH; Litière, S; Marreaud, S; Pousa, AL; Reichardt, P; Rutkowski, P; Schöffski, P; Sleijfer, S; van der Graaf, W; Verweij, J; Zalcberg, J	1
Antonescu, C; Balachandran, VP; Bertagnolli, MM; DeMatteo, RP; Fairweather, M; Li, GZ; Raut, CP; Singer, S; Tap, W	1
Antonescu, CR; Chi, P; D'Angelo, SP; DeMatteo, RP; Dickson, MA; Francis, JH; Gounder, MM; Heinemann, MH; Hwang, S; Kelly, CM; Keohan, ML; Mcfadyen, C; Qin, LX; Shoushtari, AN; Singer, S; Sjoberg, A; Tap, WD	1
Aparicio, T; Arsène, D; Bertucci, F; Bisot-Locard, S; Blay, JY; Bouché, O; Bourges, O; Cesne, AL; Chabaud, S; Chaigneau, L; Collard, O; Duffaud, F; Isambert, N; Italiano, A; Lecomte, T; Manfredi, S; Priou, F; Remy, S; Rios, M; Sambuc, R	1
Arun, B; Bast, RC; Booser, DJ; Brewster, AM; Esteva, FJ; Giordano, SH; Hortobagyi, GN; Moulder, SL; Murray, JL; Murthy, RK; Rauch, GM; Valero, V; Walters, RS; Yam, C; Yang, W	1
Beck, M; Chae, H; Kang, YK; Kim, BS; Kim, CW; Kim, JH; Kim, KH; Na, H; Ryu, MH; Yoo, C; Yoo, MW; Yook, JH	1
Li, WH; Li, WW; Wei, SC; Xu, L	1
Contreras, CM; Theiss, L	1
Alessandrino, F; Jagannathan, JP; Ramaiya, NH; Tirumani, SH	1
Patel, S	1
Bjerkehagen, B; Bruland, OS; Hole, KH; Julsrud, L; Reitan, E; Revheim, ME; Seierstad, T	1
Andersson, P; Cao, Y; Feng, N; Hosaka, K; Jensen, L; Larsson, O; Li, X; Lim, S; Nakamura, M; Ohhashi, T; Rouhi, P; Seki, T; Xue, Y; Yang, X; Yang, Y	1
Aich, RK; Das, D; Deb, AR; Ganguly, S	1
Allgayer, H; Hohenberger, P; Leupold, J; Nowak, K; Rotert, JV	1
Bertola, G; Buonadonna, A; Canzonieri, V; Gasparotto, D; Libra, M; Maestro, R; Marzotto, A; Miolo, G; Torrisi, E	1
Betz, BL; Fanta, PT; Peterson, MR; Sicklick, JK	1
Calipel, A; De La Fouchardière, A; Landreville, S; Mascarelli, F; Mouriaux, F; Penel, N; Rivoire, M	1
Bourzac, K	1
Kang, YK; Kim, BS; Kim, CW; Kim, HJ; Kim, KH; Park, SJ; Park, YS; Ryoo, BY; Ryu, MH; Sohn, BS; Yook, JH; Yu, CS	1
Doi, T; Naito, Y; Nishida, T	1
Al-Refaie, W; Atkins, MB; Parks, K; Rapisuwon, S	1
Alkatout, I; Baier, M; Bauer, M; Bauerschlag, DO; Hanson, S; Jonat, W; Maass, N; Mundhenke, C; Muth, M; Schaefer, FW; Schem, C; Tiemann, K; Weigel, MT; Wenners, AS	1
Chen, JS; Chen, TW; Chen, YY; Cheng, CT; Chiang, KC; Hsu, CC; Jan, YY; Liu, YY; Tsai, CY; Tseng, JH; Wu, CE; Yeh, CN; Yeh, TS	1
Balachandran, VP; DeMatteo, RP	1
Chen, TC; Chen, TW; Chen, YY; Cheng, CT; Chiang, KC; Jung, SM; Tsai, CY; Tseng, JH; Wang, SY; Yeh, CN; Yeh, TS	1
Brulard, C; Chibon, F; Coindre, JM; Debiec-Rychter, M; Dei Tos, P; Italiano, A; Lagarde, P; Lartigue, L; Neuville, A; Rutkowski, P; Wardelmann, E	1
Chen, H; Chen, J; Chen, Z; Shen, C; Yin, Y; Zhang, B	1
Andres, R; Calabuig, S; Casado, A; Cruz, J; De Juan, A; Del Muro, JG; Fra, J; Garcia-Albeniz, X; Lainez, N; Lopez-Pousa, A; Martin-Broto, J; Martinez-Trufero, J; Maurel, J; Poveda, A; Redondo, A; Rubió-Casadevall, J; Sevilla, I; Valverde, C	1
Aubert, S; Chauffert, B; Lebellec, L; Penel, N; Ryckewaert, T; Zaïri, F	1
Chacón, M; Eleta, M; Espindola, AR; Méndez, G; Pupareli, C; Roca, E; Rojo, S	1
Casali, PG; Cioffi, A; Gibbs, E; Goldstein, D; Joensuu, H; Kanjanapan, Y; Lee, CK; Lord, SJ; Maki, RG; Mcarthur, G; Rutkowski, P; Verweij, J; Yip, D; Zalcberg, J	1
Blay, JY; Demetri, GD; Green, S; Kang, YK; Le Cesne, A; Mo, S; Nosov, D; Novick, S; Pápai, Z; Qin, S; Reichardt, P; Rutkowski, P; Shen, L; Srimuninnimit, V; Taningco, L; Trent, J; Wan, D	1
Chen, J; Chen, Y; Luo, Z; Shi, Y; Wang, C; Zhang, R; Zheng, B	1
Glimelius, B; Golla, SS; Jonasson, M; Lubberink, M; Nygren, P; Rubin, K; Sörensen, J	1
Chang, SC; Chen, YY; Cheng, CT; Chiang, KC; Liao, CH; Liu, CT; Ma, MC; Tsai, CY; Wang, SY; Yeh, CN; Yeh, TS	1
He, ZD; Huang, XE; Zhou, JN	1
Angelini, S; Astolfi, A; Biasco, G; Nannini, M; Pantaleo, MA; Ravegnini, G	1
Deutsch, JM; Milhem, M	1
Block, J; Meng, F; Wu, G	1
Im, SA; Kang, YK; Kim, TY; Lee, SJ; Park, JO; Park, SR; Ryoo, BY; Ryu, MH; Son, MK	1
Le Cesne, A; Patrikidou, A	1
Hata, Y; Hirai, T; Ikawa, O; Ishikawa, T; Kagimura, T; Kanda, T; Masuzawa, T; Mochizuki, I; Nishida, T; Ojima, H; Sodeyama, H; Takagane, A	1
Bastian, BC; Bauer, J; Lutzky, J	1
Arun, BK; Booser, DJ; Cristofanilli, M; Francis, D; Green, MC; Hortobagyi, GN; Islam, R; Krishnamurthy, S; Lee, BN; Lopez, A; Morandi, P; Pusztai, L; Reuben, JM; Valero, V	1
de Wilt, JH; den Bakker, MA; Eggermont, AM; Mearadji, A; Sleijfer, S; van Geel, AN; Verhoef, C; Verweij, J	1
Clisant, S; Delcambre, C; Durando, X; Fournier, C; Hebbar, M; Isambert, N; Mascarelli, F; Mouriaux, F; Negrier, S; Penel, N	1
Artinyan, A; Bhatia, S; Chow, W; Ellenhorn, JD; Kim, J; Soriano, P	1
Hiraga, T; Nakamura, H	1
Hirota, S; Kubota, T; Minami, M; Nishida, T; Otani, Y; Shimada, Y; Sugino, Y; Takahashi, F; Yamamura, Y; Yanagisawa, A	1
Camci, C; Sevinc, A	1
Chang, HM; Jang, G; Kang, YK; Kim, TW; Lee, H; Lee, JL; Lee, SS; Park, I; Ryu, MH; Sym, SJ	1
Brosa, M; Díaz, S; García del Muro, X; González, P; Grande, E; Paz-Ares, L	1
Dietrich, C; Hartung, E; Ignee, A	1
Cheung, MC; Koniaris, LG; Yang, R; Zhuge, Y	1
Ichigotani, Y; Kajiya, Y; Kitagishi, Y; Matsuda, S; Okumura, N; Shirafuji, N; Yoshida, H	1
Blay, JY; Reichardt, P	1
Damaj, G; Garidi, R; Marolleau, JP; Parcelier, A; Roszkiewicz, F; Royer, B; Vaida, I	1
Casali, PG; Fiore, M; Gronchi, A; Hohenberger, P; Jakob, J; Mussi, C; Reichardt, P; Ronellenfitsch, U; Tamborini, E	1
Hyatt, BJ; Paull, PE; Wassef, W	1
Adibelli, Z; Alacacioğlu, A; Aykaş, A; Ozan, E; Oztekin, O; Postaci, H	1
Arias-Bonfill, D; Candelaria, M; Cantú, D; Chanona, J; Chávez-Blanco, A; Dueñas-González, A; Pérez, C	1
Blay, JY; Gronchi, A; Trent, JC	1
Dobrovic, A; Hamilton, AL; Handolias, D; Kerr, L; McArthur, GA; Moodie, K; Salemi, R; Tan, A	1
Ângelo, S; Moreira, JN; Pinto, AC; Simões, S	1
Hayes-Jordan, A; Kleinerman, ES; Lev, D; Mandal, D; Pollock, RE; Wang, S; Wang, Y	1
Blackstein, ME; Blay, JY; von Mehren, M	1
Chen, MF; Chen, TW; Chiang, KC; Hwang, TL; Jan, YY; Liu, YY; Tsai, CY; Tseng, JH; Wang, SY; Yeh, CN	1
Blanke, CD; Huse, DM	1
von Mehren, M; Widmer, N	1
Kishimoto, H; Nakamura, M; Otagiri, N; Sasahara, K; Tauchi, K; Tsukada, Y; Yoshifuku, S	1
Casali, PG; Collini, P; Conca, E; Gronchi, A; Keslair, F; Marrari, A; Morosi, C; Negri, T; Palassini, E; Pedeutour, F; Pilotti, S; Stacchiotti, S	1
Alacacioglu, A; Camci, C; Dikilitas, M; Er, O; Kalender, ME; Sagol, O; Sari, I; Sevinc, A; Soyuer, I; Yilmaz, U	1
Diebold, J; Hirschmann, A; Rössle, M	1
Chayama, K; Kitadai, Y; Kodama, M; Ohara, E; Ohnishi, M; Shinagawa, K; Sumida, T; Tanaka, M; Tanaka, S; Yasui, W	1
Kamiya, K; Kikuchi, H; Konno, H; Miyazaki, S; Ohta, M; Sakaguchi, T; Setoguchi, T; Yamamoto, M	1
Davion, S; Kulesza, P; Nayar, R; Rohan, S	1
Antonescu, CR; Bastian, BC; Bouvier, N; Busam, KJ; Cane, L; Carvajal, RD; Chapman, PB; Chmielowski, B; Fusco, A; Lutzky, J; Panageas, KS; Pavlick, AC; Roman, RA; Schwartz, GK; Takebe, N; Teitcher, J; Vemula, S; Wolchok, JD	1
Cao, Y; Dewhirst, MW; Han, S; Hara, MR; Oliver, T; Shenoy, SK; Zhao, YL	1
Blay, JY; Bompas, E; Cassier, PA; Dômont, J; Gelderblom, H; Italiano, A; Kroep, JR; Maki, RG; Seddon, B; Stacchiotti, S; Thomas, D; van der Graaf, WT; Wagner, AJ	1
Li, QW; Lu, JY; Sun, JZ; Wang, RL; Xiao, WH; Zhu, JH	1
Buti, S; Donini, M; Garagnani, L; Passalacqua, R; Rossi, G; Schirosi, L; Sergio, P	1
Caram, MV; Schuetze, SM	1
Ashley, SW; Grover, S; Raut, CP	1
Chika, N; Kakimoto, M; Kikuchi, A; Koshiishi, H; Nishida, K; Okamura, T; Tokita, H; Yoshimura, T	1
Brentani, RR; Cooke, VG; Damascena, A; Duncan, MB; Kalluri, R; Keskin, D; Khan, Z; LeBleu, VS; Maeda, G; O'Connell, JT; Rocha, RM; Sugimoto, H; Teng, Y; Vong, S; Xie, L	1
Bamboat, ZM; Dematteo, RP	1
Chung, AS; Ferrara, N; Finkle, D; Komuves, L; Kowanetz, M; Ngu, H; Peale, F; Wu, X; Zhuang, G	1
Butrynski, JE; Choy, E; Corless, CL; Demetri, GD; Fletcher, JA; George, S; Heinrich, MC; Manola, JB; Morgan, JA; Solomon, SM; Tap, WD; Van den Abbeele, AD; von Mehren, M; Wagner, AJ; Wang, Q; Yap, JT; Zhu, M	1
Donohue, JH; Nagorney, DM; Okuno, SH; Que, FG; Zaydfudim, V	1
Carrió-Gasset, I; Fuertes-Cabero, S; García-Garzón, JR; Lomeña-Caballero, F; Moragas-Solanes, M; Ponce-López, A; Riera-Gil, E; Soler-Peter, M; Valls-Ferrusola, E	1
Gronchi, A; Hohenberger, P; Jakob, J; Mussi, C; Negri, T; Ronellenfitsch, U; Wardelmann, E	1
Dummer, R; Eggmann, N; Goldinger, SM; Rinderknecht, J; Rozati, S	1
Bi, C; Cheong, LL; Chng, WJ; Chong, PS; Liu, SC; Mahara, S; Ong, KO; Zeng, Q; Zhou, J	1
Bekers, DJ; Eechoute, K; Krestin, GP; Mathijssen, RH; Ruggiero, A; Schiavon, G; Schöffski, P; Sleijfer, S; van der Holt, B; Vandecaveye, V; Verweij, J	1
Donnenberg, AD; Donnenberg, VS; Landreneau, RJ; Luketich, JD; Zimmerlin, L	1
Gonda, H; Ikeda, K; Izumi, H; Kitamura, D; Seki, E; Unotoro, J	1
Akinci, MB; Aksoy, S; Ozdemir, NY; Sendur, MA; Uncu, D; Zengin, N	1
Ando, T; Hosokawa, A; Kajiura, S; Nakata, K; Saito, S; Sugiyama, T	1
George, DJ	1
Houshmand, P; Zlotnik, A	1
Binckebanck, A; Brück, P; Gökbuget, N; Gschaidmeier, H; Hoelzer, D; Hofmann, WK; Komor, M; Leimer, L; Lübbert, M; Ottmann, OG; Pfeifer, H; Scheuring, U; Schleyer, E; Wassmann, B; Wolff, T	1
Babu, KG; Bapsy, PP; Girish, MH; Prabhash, K	1
Bucana, CD; Evans, DB; Fidler, IJ; Hwang, RF; Killion, JJ; Tsan, R; Yokoi, K	1
Cunningham, SC; Shibata, D; Volpe, C	1
Hohenberger, P; Pink, D; Reichardt, P; Schneider, U; Stroszczynski, C	1
Duensing, A; Fletcher, CD; Fletcher, JA; Heinrich, MC	1
Eisenberg, BL; Judson, I	1
Egorin, MJ; Ilaria, RL; Minna, JD; Randle, DE; Wolff, NC	1
Sawaki, A; Yamao, K	1
Gebauer, B; Hohenberger, P; Reichardt, P; Wardelmann, E	1
Blackstein, ME; Dubé, P; Fletcher, JA; Keller, OR; Knowling, M; Létourneau, R; Morris, D; Riddell, R; Rorke, S; Swallow, CJ	1
Fidler, IJ; Kim, SJ; Lev, DC; Nam, DH; Onn, A; Price, JE; Stone, V; Yazici, S	1
Fernandez, CV; Rigby, H; Schmidt, MH; Yu, W	1
Franceschini, R; Garuti, A; Gobbi, M; Zoppi, F	1
Armbrust, T; Füzesi, L; Gunawan, B; Langer, C; Ramadori, G; Schindler, CG	1
D'Andrea, G; Dickler, M; Hudis, CA; Menell, J; Moasser, M; Modi, S; Moynahan, ME; Norton, L; Panageas, KS; Seidman, AD; Tan, LK	1
Abdulkader, I; Cameselle-Teijeiro, J; Forteza, J	1
Bihl, H; Büttner, R; Heinicke, T; Hohenberger, P; Leutner, CC; Merkelbach-Bruse, S; Pauls, K; Speidel, N; Thomas, N; Wardelmann, E	1
Becker, JC; Hildenbrand, R; Hochhaus, A; Keikavoussi, P; La Rosée, P; Paschka, P; Rittgen, W; Schadendorf, D; Sucker, A; Ugurel, S; Zimpfer, A	1
Antoch, G; Bauer, S; de Wit, M; Ebeling, P; Erhard, J; Flasshove, M; Grabellus, F; Hartmann, JT; Lang, H; Niebel, W; Schütte, J; Seeber, S; Taeger, G; Zeth, M	1
Connock, M; Fry-Smith, A; Peake, D; Raftery, J; Song, F; Wilson, J; Yao, G	1
Alexis, JB; Lutzky, J; Martinez, AE	1
DeMatteo, RP; van der Zwan, SM	1
Apice, G; Botti, G; De Chiara, A; De Rosa, V; Franco, R; Iaffaioli, VR; Lastoria, S	1
Bauer, S; Hartmann, JT; Lang, H; Schütte, J	1
Bertagnolli, MM; Demetri, GD; Fletcher, CD; George, S; Hornick, JL	1
Liu, YK; Qin, LX; Sun, HC; Tang, ZY; Wang, L; Wu, WZ; Xu, Y; Ye, SL; Zhang, KZ; Zhang, T	1
Benjamin, RS; Blanke, CD; Blay, JY; Bonvalot, S; Eisenberg, B	1
Goldstein, D; Harrison, ML	1
Beug, H; Capodiecci, P; Cordon-Cardo, C; Donovan, M; Grünert, S; Jechlinger, M; Kraut, N; Moriggl, R; Seither, P; Sommer, A	1
Fidler, IJ	1
Avril, MF; Chouaib, S; Faure, F; Hamaï, A; Jalil, A; Kauffmann, A; Larue, L; Lecluse, Y; Mehrpour, M; Meslin, F; Richon, C	1
Blanke, CD; Schnadig, ID	1
Awada, A; De Saint Aubain, N; Flamen, P; Gil, T; Kasper, B; Lossignol, D	1
Kibble, A	1
Hohenberger, P	1
Gelderblom, H; Guchelaar, HJ; Oostendorp, RL; Schellens, JH; van Erp, NP	1
Heldin, CH; Ostman, A	1
Maki, RG	1
Darwiche, SS; El-Kinge, N; Jamali, FR; Soweid, AM; Tawil, A	1
Benjamin, RS; Burgess, MA; Charnsangavej, C; Chen, LL; Choi, H; Faria, SC; Macapinlac, HA; Patel, SR; Podoloff, DA	1
Benjamin, RS; Burgess, MA; Charnsangavej, C; Chen, LL; Choi, H; Macapinlac, HA; Patel, SR; Podoloff, DA	1
Fukuda, M; Hasegawa, J; Hatakeyama, K; Hirota, S; Kanda, T; Kurosaki, I; Nishida, T; Nishitani, A; Takahashi, T; Tsutsui, S	1
de Groot, JW; de Vries, MM; Links, TP; Lips, CJ; van Ufford-Mannesse, PQ; Voest, EE; Zonnenberg, BA	1
Chosia, M; Kraszewska, E; Lasota, J; Michej, W; Miettinen, M; Ogun, G; Ptaszynski, K; Ruka, W; Rutkowski, P; Sarlomo-Rikala, M; Schneider-Stock, R; Siedlecki, JA; Stachura, J; Steigen, SE; vel Dobosz, AJ; Wasag, B; Wozniak, A	1
Bucana, CD; Cohen, L; Fidler, IJ; Johnson, MM; Jones, DM; Kim, SJ; Logothetis, CJ; Mathew, P; Meluch, AA; Morris, MJ; Oh, WK; Pagliaro, LC; Smith, L; Tannir, NM; Thall, PF; Troncoso, P; Tu, SM; Wen, S	1
Jatchavala, J; Phaisanphrukkun, C; Phongkitkarun, S; Sirachainan, E	1
Caldara, A; Graiff, C; Mandarà, M; Pedersini, R; Sava, T; Vattemi, E	1
Gharibo, M; Guensch, L; Juvidian, P; Patrick-Miller, L; Poplin, E; Zheng, L	1
Hou, M; Li, HY; Wang, Y; Zhang, J; Zhu, J	1
Demetri, GD	1
Blanke, CD; Eisenberg, BL; Heinrich, MC	1

Reviews

41 review(s) available for imatinib mesylate and Neoplasm Metastasis

Article	Year
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus	2016
The management of metastatic GIST: current standard and investigational therapeutics. Journal of hematology & oncology, 2021, 01-05, Volume: 14, Issue:1 Topics: Animals; Antineoplastic Agents; Disease Management; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sunitinib	2021
Gastrointestinal Stromal Tumors of the Stomach and Esophagus. The Surgical clinics of North America, 2019, Volume: 99, Issue:3 Topics: Aftercare; Antineoplastic Agents; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Esophageal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Humans; Imatinib Mesylate; Laparoscopy; Neoplasm Metastasis; Prognosis; Proto-Oncogene Mas; Stomach Neoplasms; Tomography, X-Ray Computed	2019
Imaging surveillance of gastrointestinal stromal tumour: current recommendation by National Comprehensive Cancer Network and European Society of Medical Oncology-European Reference Network for rare adult solid cancers. Clinical radiology, 2019, Volume: 74, Issue:10 Topics: Chemotherapy, Adjuvant; Continuity of Patient Care; Contrast Media; Diagnostic Imaging; Drug Resistance, Neoplasm; Early Diagnosis; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Practice Guidelines as Topic; Protein Kinase Inhibitors; Risk Assessment	2019
Long-term efficacy of imatinib for treatment of metastatic GIST. Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:2 Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; DNA Mutational Analysis; Dose-Response Relationship, Drug; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Patient Compliance; Piperazines; Pyrimidines; Survival Analysis; Treatment Outcome	2013
Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:14 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Metastasis; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib	2014
Gastrointestinal stromal tumors: who should get imatinib and for how long? Advances in surgery, 2014, Volume: 48 Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Drug Resistance; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2014
Molecular targeted therapies in advanced or metastatic chordoma patients: facts and hypotheses. Critical reviews in oncology/hematology, 2015, Volume: 95, Issue:1 Topics: Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Chordoma; ErbB Receptors; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptors, Platelet-Derived Growth Factor; Vascular Endothelial Growth Factor A	2015
miRNA profiling in gastrointestinal stromal tumors: implication as diagnostic and prognostic markers. Epigenomics, 2015, Volume: 7, Issue:6 Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Chromosome Deletion; Chromosomes, Human, Pair 14; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; MicroRNAs; Mutation; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Transcriptome	2015
Imatinib Dosing in Gastrointestinal Stromal Tumors (GISTs): When, How Much, and How Long? Current clinical pharmacology, 2015, Volume: 10, Issue:4 Topics: Antineoplastic Agents; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Protein Kinase Inhibitors; Survival Analysis; Time Factors	2015
Key messages from the BFR14 trial of the French Sarcoma Group. Future oncology (London, England), 2017, Volume: 13, Issue:3 Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Disease Progression; France; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Sarcoma; Treatment Outcome	2017
Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations. Expert review of anticancer therapy, 2009, Volume: 9, Issue:6 Topics: Antineoplastic Agents; Benzamides; Disease Progression; DNA Mutational Analysis; Europe; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Metastasis; Piperazines; Practice Guidelines as Topic; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib	2009
Tyrosine kinase inhibitors and solid tumours: case report and review of the literature. Pharmacology, 2009, Volume: 84, Issue:1 Topics: Administration, Oral; Benzamides; Carcinoma; Dasatinib; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2009
Gastric oncology: an update. Current opinion in gastroenterology, 2009, Volume: 25, Issue:6 Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Benzamides; Endoscopy, Gastrointestinal; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lymphoma, B-Cell, Marginal Zone; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Pyrimidines; Stomach Neoplasms	2009
Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Mar-01, Volume: 28, Issue:7 Topics: Antineoplastic Agents; Benzamides; Disease-Free Survival; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mutation; Neoplasm Metastasis; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines	2010
The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor. Cancer, 2010, Apr-15, Volume: 116, Issue:8 Topics: Benzamides; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2010
Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors. Cancer, 2010, Nov-15, Volume: 116, Issue:22 Topics: Benzamides; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Practice Guidelines as Topic; Pyrimidines; Recurrence	2010
Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors. Journal of medical economics, 2010, Volume: 13, Issue:4 Topics: Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Models, Economic; Neoplasm Metastasis; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib	2010
Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing? Cancer treatment reviews, 2011, Volume: 37, Issue:4 Topics: Antineoplastic Agents; Benzamides; Drug Monitoring; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Patient Compliance; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2011
Metastatic chromophobe renal cell carcinoma in pleural fluid cytology: review of literature and report of a case. Diagnostic cytopathology, 2012, Volume: 40, Issue:9 Topics: Benzamides; Carcinoma, Renal Cell; Cell Membrane; Cytoplasm; Humans; Imatinib Mesylate; Immunohistochemistry; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pleura; Pleural Effusion, Malignant; Proto-Oncogene Proteins c-kit; Pyrimidines	2012
Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options. Journal of surgical oncology, 2011, Volume: 104, Issue:8 Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib	2011
Small intestine gastrointestinal stromal tumors. Current opinion in gastroenterology, 2012, Volume: 28, Issue:2 Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intestinal Neoplasms; Intestine, Small; Neoadjuvant Therapy; Neoplasm Metastasis; Piperazines; Prognosis; Pyrimidines; Pyrroles; Sunitinib	2012
Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate. Urology, 2002, Volume: 60, Issue:3 Suppl 1 Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Drug Resistance, Neoplasm; Hormones; Humans; Imatinib Mesylate; Male; Neoplasm Metastasis; Piperazines; Prostatectomy; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Treatment Outcome	2002
Targeting tumor cells. Current opinion in cell biology, 2003, Volume: 15, Issue:5 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Benzamides; Chemokines; Drug Therapy; Gene Expression Profiling; Genes, abl; Genes, erbB-2; Humans; Imatinib Mesylate; Integrins; Leukemia, Myelomonocytic, Chronic; Lymphoma, Non-Hodgkin; Metalloproteases; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Rituximab; Stomach Neoplasms; Trastuzumab	2003
Gastrointestinal stromal tumour--a paradigm shift in management of solid tumours. The Journal of the Association of Physicians of India, 2003, Volume: 51 Topics: Antineoplastic Agents; Benzamides; Embolization, Therapeutic; Enzyme Inhibitors; Gastrointestinal Neoplasms; Genetic Markers; Humans; Imatinib Mesylate; Immunohistochemistry; Neoplasm Metastasis; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiotherapy, Adjuvant	2003
Biology of gastrointestinal stromal tumors: KIT mutations and beyond. Cancer investigation, 2004, Volume: 22, Issue:1 Topics: Benzamides; Cell Transformation, Neoplastic; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Stromal Cells	2004
Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Annals of surgical oncology, 2004, Volume: 11, Issue:5 Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Neoplasm Metastasis; Patient Selection; Piperazines; Prognosis; Pyrimidines; Risk Assessment; Stromal Cells; Survival Analysis	2004
Imatinib mesylate acts in metastatic or unresectable gastrointestinal stromal tumor by targeting KIT receptors--a review. Cancer chemotherapy and pharmacology, 2004, Volume: 54 Suppl 1 Topics: Benzamides; Drug Delivery Systems; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Neoplasm Metastasis; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines	2004
[Gastrointestinal stromal tumors (GIST)--current concepts of surgical management]. Deutsche medizinische Wochenschrift (1946), 2004, Aug-20, Volume: 129, Issue:34-35 Topics: Benzamides; Chemotherapy, Adjuvant; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leiomyoma; Leiomyoma, Epithelioid; Leiomyosarcoma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neurilemmoma; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors	2004
Gastrointestinal stromal tumours: etiology, pathology and clinical management. Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2004, Volume: 18 Suppl B Topics: Antineoplastic Agents; Benzamides; Cell Death; Cell Differentiation; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Piperazines; Pyrimidines; Signal Transduction	2004
Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. Health technology assessment (Winchester, England), 2005, Volume: 9, Issue:25 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Controlled Clinical Trials as Topic; Cost-Benefit Analysis; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; State Medicine; United Kingdom	2005
Gastrointestinal stromal tumor: 5 years later. Cancer, 2005, Nov-01, Volume: 104, Issue:9 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines	2005
Management of gastrointestinal stromal tumors in the imatinib era: selected case studies. The oncologist, 2006, Volume: 11, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Aortic Aneurysm, Abdominal; Benzamides; Chemotherapy, Adjuvant; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Tomography, X-Ray Computed	2006
Management of metastatic gastrointestinal stromal tumour in the Glivec era: a practical case-based approach. Internal medicine journal, 2006, Volume: 36, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines	2006
Gastrointestinal stromal tumors: imatinib and beyond. Current treatment options in oncology, 2006, Volume: 7, Issue:6 Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib	2006
[Gastrointestinal stromal tumors]. Praxis, 2007, Jan-10, Volume: 96, Issue:1-2 Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Metastasis; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors	2007
PDGF receptors as targets in tumor treatment. Advances in cancer research, 2007, Volume: 97 Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Extracellular Fluid; Fibroblasts; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Piperazines; Platelet-Derived Growth Factor; Pressure; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Sunitinib; Translocation, Genetic	2007
Recent advances in therapy for gastrointestinal stromal tumors. Current oncology reports, 2007, Volume: 9, Issue:3 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib	2007
Systemic therapies for recurrent and/or metastatic salivary gland cancers. Expert review of anticancer therapy, 2008, Volume: 8, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Boronic Acids; Bortezomib; Cetuximab; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Piperazines; Pyrazines; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Trastuzumab	2008
Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Seminars in oncology, 2001, Volume: 28, Issue:5 Suppl 17 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Mesoderm; Mutation; Neoplasm Metastasis; Piperazines; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines	2001
Gastrointestinal stromal tumors. Current treatment options in oncology, 2001, Volume: 2, Issue:6 Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Chemotherapy, Adjuvant; Combined Modality Therapy; Digestive System Surgical Procedures; Enzyme Inhibitors; Epidemiologic Methods; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Immunotherapy; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasms, Connective Tissue; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome	2001

Trials

24 trial(s) available for imatinib mesylate and Neoplasm Metastasis

Article	Year
Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial. European journal of cancer (Oxford, England : 1990), 2019, Volume: 121 Topics: Administration, Oral; Aged; Benzamides; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Japan; Male; Middle Aged; Neoplasm Metastasis; Phenylurea Compounds; Pyrazoles; Pyridines; Sunitinib; Treatment Outcome	2019
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus	2016
Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Tr Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, May-20, Volume: 35, Issue:15 Topics: Adult; Aged; Antineoplastic Agents; Cross-Over Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prognosis	2017
A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. Investigational new drugs, 2019, Volume: 37, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Receptors, Fibroblast Growth Factor; Tissue Distribution	2019
A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β. Investigational new drugs, 2018, Volume: 36, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Female; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Letrozole; Middle Aged; Neoplasm Metastasis; Progression-Free Survival; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor beta; Treatment Outcome	2018
Neoodjuvant imatinib mesylate for advanced primary and metastactic/recurrent gastro-intestinal stromal tumour (GIST). Journal of the Indian Medical Association, 2013, Volume: 111, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Digestive System Surgical Procedures; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Preoperative Care; Pyrimidines; Treatment Outcome	2013
Final safety and efficacy analysis of a phase I/II trial with imatinib and vinorelbine for patients with metastatic breast cancer. Oncology, 2014, Volume: 87, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Female; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Metastasis; Piperazines; Prospective Studies; Pyrimidines; Vinblastine; Vinorelbine	2014
Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Nomograms; Piperazines; Prognosis; Pyrimidines; Survival Analysis; Young Adult	2015
Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. The Lancet. Oncology, 2015, Volume: 16, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Treatment Outcome	2015
Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program. Cancer research and treatment, 2017, Volume: 49, Issue:2 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retreatment; Sunitinib; Treatment Failure; Treatment Outcome	2017
Surgery and imatinib therapy for liver oligometastasis of GIST: a study of Japanese Study Group on GIST. Japanese journal of clinical oncology, 2017, Apr-01, Volume: 47, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Japan; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Salvage Therapy	2017
Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:10 Topics: Adult; Antineoplastic Agents; Benzamides; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Female; Humans; Imatinib Mesylate; Immunologic Factors; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta	2008
O-Mel-Inib: a Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma. Investigational new drugs, 2008, Volume: 26, Issue:6 Topics: Abdominal Pain; Administration, Oral; Aged; Antineoplastic Agents; Benzamides; Disease Progression; Female; Humans; Imatinib Mesylate; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Survival Rate; Uveal Neoplasms	2008
Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2008, Volume: 10, Issue:12 Topics: Algorithms; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Health Resources; Humans; Imatinib Mesylate; Indoles; Markov Chains; Models, Econometric; Neoplasm Metastasis; Piperazines; Placebos; Pyrimidines; Pyrroles; Sunitinib; Survival Analysis; Treatment Failure	2008
Lack in efficacy for imatinib mesylate as second-line treatment of recurrent or metastatic cervical cancer expressing platelet-derived growth factor receptor alpha. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2009, Volume: 19, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Recurrence; Survival Analysis; Treatment Outcome; Uterine Cervical Neoplasms	2009
KIT as a therapeutic target in metastatic melanoma. JAMA, 2011, Jun-08, Volume: 305, Issue:22 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Female; Humans; Imatinib Mesylate; Male; Melanoma; Middle Aged; Mutation; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms; Survival Analysis; Treatment Outcome	2011
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jul-01, Volume: 30, Issue:19 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasm Metastasis; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome	2012
Gastrointestinal stromal tumor (GIST) -- single center experience of prolonged treatment with imatinib. Zeitschrift fur Gastroenterologie, 2005, Volume: 43, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; DNA, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nucleic Acid Hybridization; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Risk Factors; Safety; Time Factors; Tomography, X-Ray Computed	2005
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast cancer research and treatment, 2005, Volume: 90, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Survival Rate	2005
Lack of clinical efficacy of imatinib in metastatic melanoma. British journal of cancer, 2005, Apr-25, Volume: 92, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Base Sequence; Benzamides; Cell Line, Tumor; Cell Proliferation; DNA Mutational Analysis; Female; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Melanoma; Middle Aged; Molecular Sequence Data; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome	2005
Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. International journal of cancer, 2005, Nov-01, Volume: 117, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm, Residual; Piperazines; Pyrimidines; Survival Analysis; Time Factors	2005
A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Medullary; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Thyroid Neoplasms; Treatment Outcome	2007
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Oct-01, Volume: 13, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Castration; Cohort Studies; Disease-Free Survival; Docetaxel; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Placebos; Prostatic Neoplasms; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor; Taxoids	2007
A phase II trial of imatinib mesylate in patients with metastatic pancreatic cancer. Pancreas, 2008, Volume: 36, Issue:4 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease Progression; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Patient Selection; Piperazines; Pyrimidines; Time Factors	2008

Other Studies

101 other study(ies) available for imatinib mesylate and Neoplasm Metastasis

Article	Year
Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor. Scientific reports, 2019, 10-10, Volume: 9, Issue:1 Topics: Adult; Antineoplastic Agents; Australia; Disease Progression; Disease-Free Survival; Europe; Female; Giant Cell Tumor of Tendon Sheath; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Metastasis; Receptors, Colony-Stimulating Factor; Retrospective Studies; Treatment Outcome; United States	2019
Combination of pembrolizumab and imatinib in a patient with double KIT mutant melanoma: A case report. Medicine, 2019, Volume: 98, Issue:44 Topics: Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Imatinib Mesylate; Melanoma; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins c-kit; Skin Neoplasms; Treatment Outcome	2019
Multidrug resistant gastrointestinal stromal tumor with multiple metastases to the skin and subcutaneous soft tissue: A case report and review of literature. Journal of cutaneous pathology, 2020, Volume: 47, Issue:4 Topics: Adult; Aged; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Skin Neoplasms; Sunitinib	2020
Targeting AXL and RAGE to prevent geminin overexpression-induced triple-negative breast cancer metastasis. Scientific reports, 2019, 12-16, Volume: 9, Issue:1 Topics: Animals; Axl Receptor Tyrosine Kinase; Cancer-Associated Fibroblasts; Cell Line, Tumor; Cell Polarity; Female; Geminin; Humans; Imatinib Mesylate; Macrophage Activation; Macrophages; Mesenchymal Stem Cells; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Proto-Oncogene Proteins; Receptor for Advanced Glycation End Products; Receptor Protein-Tyrosine Kinases; S100 Calcium-Binding Protein A4; Triple Negative Breast Neoplasms	2019
Preoperative imatinib treatment in patients with locally advanced and metastatic/recurrent gastrointestinal stromal tumors: A single-center analysis. Medicine, 2020, Volume: 99, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; China; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Medical Records; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Retrospective Studies; Survival Analysis; Treatment Outcome	2020
Cost-effectiveness Analysis of Genetic Testing and Tailored First-Line Therapy for Patients With Metastatic Gastrointestinal Stromal Tumors. JAMA network open, 2020, 09-01, Volume: 3, Issue:9 Topics: Antineoplastic Agents; Cost-Benefit Analysis; Drug Costs; Gastrointestinal Stromal Tumors; Genetic Testing; Humans; Imatinib Mesylate; Markov Chains; Neoplasm Metastasis; Neoplasm Staging; Pharmacogenetics; Proto-Oncogene Proteins c-kit; Quality-Adjusted Life Years	2020
Gastric Gastrointestinal Stromal Tumor with Repeated Recurrence at the Anastomosis Site in a Very Elderly Patient. The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2020, 10-25, Volume: 76, Issue:4 Topics: Abdomen; Aged, 80 and over; Endoscopy, Gastrointestinal; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Tomography, X-Ray Computed	2020
Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2021, Volume: 47, Issue:8 Topics: Aged; Anastomotic Leak; Antineoplastic Agents; Biopsy, Fine-Needle; Chemotherapy, Adjuvant; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; Europe; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Margins of Excision; Middle Aged; Mitotic Index; Neoadjuvant Therapy; Neoplasm Metastasis; Plastic Surgery Procedures; Postoperative Complications; Progression-Free Survival; Retrospective Studies; Treatment Outcome; Tumor Burden	2021
Gastrointestinal stromal tumor of the stomach with axillary lymph node metastasis: A case report. World journal of gastroenterology, 2017, Mar-07, Volume: 23, Issue:9 Topics: Aged; Axilla; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Lymph Nodes; Lymphatic Metastasis; Male; Neoplasm Metastasis; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Pyrroles; Stomach Neoplasms; Sunitinib; Tomography, X-Ray Computed	2017
Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors: A 2-institutional Analysis. Annals of surgery, 2018, Volume: 268, Issue:2 Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Metastasectomy; Neoplasm Metastasis; Prognosis; Retrospective Studies; Sunitinib; Survival Analysis	2018
EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib. PloS one, 2018, Volume: 13, Issue:9 Topics: Adult; Aged; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Edema; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins c-kit; Treatment Outcome	2018
Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience. Cancer medicine, 2019, Volume: 8, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cancer Survivors; Cohort Studies; Combined Modality Therapy; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Survival Rate; Treatment Outcome; Young Adult	2019
Malignant jejunal gastrointestinal stromal tumor with history of prostate cancer: A case report. Medicine, 2019, Volume: 98, Issue:18 Topics: Aged; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Metastasis; Peritoneal Neoplasms; Postoperative Complications; Prostatic Neoplasms; Protein Kinase Inhibitors; Tomography, X-Ray Computed; Treatment Outcome	2019
Multimodal functional imaging for early response assessment in GIST patients treated with imatinib. Acta oncologica (Stockholm, Sweden), 2014, Volume: 53, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Feasibility Studies; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome	2014
Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis. Nature communications, 2013, Volume: 4 Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Becaplermin; Benzamides; Carcinoma, Lewis Lung; Cell Movement; Cell Proliferation; Fibrosarcoma; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Integrin alpha1beta1; Lung Neoplasms; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Pericytes; Piperazines; Proto-Oncogene Proteins c-sis; Pyrimidines; Signal Transduction; Xenograft Model Antitumor Assays	2013
Src activity is increased in gastrointestinal stromal tumors--analysis of associations with clinical and other molecular tumor characteristics. Journal of surgical oncology, 2014, Volume: 109, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; src-Family Kinases; Vascular Endothelial Growth Factor A	2014
Improved outcome with multimodal treatment and imatinib rechallenge in advanced GIST. International journal of colorectal disease, 2014, Volume: 29, Issue:5 Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Treatment Outcome	2014
In vivo imatinib sensitivity in a patient with GI stromal tumor bearing a PDGFRA deletion DIM842-844. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Mar-10, Volume: 33, Issue:8 Topics: Aged; Antineoplastic Agents; Benzamides; Biopsy; DNA Mutational Analysis; Exons; Gastrointestinal Stromal Tumors; Gene Deletion; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Mutation; Necrosis; Neoplasm Metastasis; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Tomography, X-Ray Computed	2015
Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma. Clinical & experimental metastasis, 2014, Volume: 31, Issue:5 Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression; Humans; Imatinib Mesylate; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Stem Cell Factor; Treatment Outcome; Uveal Neoplasms	2014
Biology: Three known unknowns. Nature, 2014, May-29, Volume: 509, Issue:7502 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biological Evolution; Drug Resistance, Neoplasm; Genes, Tumor Suppressor; Humans; Imatinib Mesylate; Immunity; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Metastasis; Neoplasms; Piperazines; Pyrimidines; Tumor Microenvironment	2014
The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses. Annals of surgical oncology, 2014, Volume: 21, Issue:13 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Prognosis; Propensity Score; Pyrimidines; Retrospective Studies; Survival Rate; Young Adult	2014
Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report. Melanoma research, 2014, Volume: 24, Issue:5 Topics: Antineoplastic Agents; Benzamides; Biopsy; DNA Mutational Analysis; Exons; Fatal Outcome; Female; Humans; Imatinib Mesylate; Melanoma; Middle Aged; Mucous Membrane; Mutation; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms; Stem Cell Factor	2014
Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients. Anticancer research, 2014, Volume: 34, Issue:9 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Drug Substitution; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Neoplasm Metastasis; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Retreatment; Sunitinib; Treatment Outcome; Young Adult	2014
Clinical significance of pathological complete response in patients with metastatic gastrointestinal stromal tumors after imatinib mesylate treatment--lessons learned. Anticancer research, 2014, Volume: 34, Issue:11 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Prognosis; Prospective Studies; Pyrimidines; Remission Induction; Survival Rate	2014
Genomic index predicts clinical outcome of intermediate-risk gastrointestinal stromal tumours, providing a new inclusion criterion for imatinib adjuvant therapy. European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:1 Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Metastasis; Piperazines; Prognosis; Pyrimidines; Treatment Outcome	2015
Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor. Clinics (Sao Paulo, Brazil), 2014, Volume: 69, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Preoperative Care; Preoperative Period; Pyrimidines; Reproducibility of Results; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden	2014
Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS). Annals of surgical oncology, 2015, Volume: 22, Issue:9 Topics: Antineoplastic Agents; Combined Modality Therapy; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Metastasectomy; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate	2015
Assessment of early response to imatinib 800 mg after 400 mg progression by ¹⁸F-fluorodeoxyglucose PET in patients with metastatic gastrointestinal stromal tumors. Future oncology (London, England), 2015, Volume: 11, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Female; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Image Interpretation, Computer-Assisted; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome	2015
Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients. Medicine, 2015, Volume: 94, Issue:17 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; China; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Retrospective Studies; Skin Neoplasms; Treatment Outcome	2015
(15)O-Water PET Study of the Effect of Imatinib, a Selective Platelet-Derived Growth Factor Receptor Inhibitor, Versus Anakinra, an IL-1R Antagonist, on Water-Perfusable Tissue Fraction in Colorectal Cancer Metastases. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015, Volume: 56, Issue:8 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzamides; Colorectal Neoplasms; Female; Humans; Imatinib Mesylate; Interleukin 1 Receptor Antagonist Protein; Kinetics; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Oxygen Radioisotopes; Perfusion; Piperazines; Positron-Emission Tomography; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Reproducibility of Results; Time Factors; Water	2015
Feasibility and Timing of Cytoreduction Surgery in Advanced (Metastatic or Recurrent) Gastrointestinal Stromal Tumors During the Era of Imatinib. Medicine, 2015, Volume: 94, Issue:24 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Prognosis; Prospective Studies; Pyrimidines; Retrospective Studies; Severity of Illness Index; Survival Analysis; Time Factors	2015
Clinical Observations on Treatment for Chinese Patients with Gastrointestinal Stromal Tumors. Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Digestive System Surgical Procedures; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Preoperative Care; Prognosis; Retrospective Studies; Survival Rate	2015
Reversing cancer stemness. Aging, 2015, Volume: 7, Issue:11 Topics: Epithelial-Mesenchymal Transition; Humans; Imatinib Mesylate; Neoplasm Metastasis; Neoplasms; Neoplastic Stem Cells; Receptor, Platelet-Derived Growth Factor alpha	2015
Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment cell & melanoma research, 2008, Volume: 21, Issue:4 Topics: Aged; Amino Acid Substitution; Anus Neoplasms; Benzamides; Dose-Response Relationship, Drug; Female; Glutamic Acid; Humans; Imatinib Mesylate; Intestinal Mucosa; Lysine; Melanoma; Neoplasm Metastasis; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction	2008
Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis. Anti-cancer drugs, 2008, Volume: 19, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Combined Modality Therapy; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines	2008
Metastatic gastrointestinal stromal tumors in the era of imatinib: improved survival and elimination of socioeconomic survival disparities. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2008, Volume: 17, Issue:8 Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Healthcare Disparities; Humans; Imatinib Mesylate; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Piperazines; Proportional Hazards Models; Pyrimidines; SEER Program; Socioeconomic Factors; Survival Rate; United States	2008
Imatinib mesylate suppresses bone metastases of breast cancer by inhibiting osteoclasts through the blockade of c-Fms signals. International journal of cancer, 2009, Jan-01, Volume: 124, Issue:1 Topics: Animals; Antineoplastic Agents; Benzamides; Bone and Bones; Bone Neoplasms; Cell Line; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Mice; Mice, Nude; Neoplasm Metastasis; Osteoclasts; Piperazines; Pyrimidines; Receptor, Macrophage Colony-Stimulating Factor	2009
Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version. International journal of clinical oncology, 2008, Volume: 13, Issue:5 Topics: Algorithms; Antineoplastic Agents; Benzamides; Diagnostic Imaging; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines	2008
'Time is a GIFT in GIST'--the medical and paramedical perspective of a case with metastatic gastrointestinal stromal tumor. Chemotherapy, 2009, Volume: 55, Issue:1 Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leiomyosarcoma; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms, Muscle Tissue; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Tomography, X-Ray Computed	2009
Dose escalation of imatinib after failure of standard dose in Korean patients with metastatic or unresectable gastrointestinal stromal tumor. Japanese journal of clinical oncology, 2009, Volume: 39, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Asian People; Benzamides; Disease Progression; DNA Mutational Analysis; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Korea; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Survival Rate; Treatment Failure	2009
The use of contrast-enhanced ultrasound in patients with GIST metastases that are negative in CT and PET. Ultraschall in der Medizin (Stuttgart, Germany : 1980), 2008, Volume: 29 Suppl 5 Topics: Adult; Antineoplastic Agents; Benzamides; Contrast Media; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Ultrasonography	2008
Diagnosing gastrointestinal stromal tumors before the year 2000. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2009, Volume: 18, Issue:3 Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Healthcare Disparities; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; SEER Program; Socioeconomic Factors; Survival Rate; United States	2009
NESH protein expression switches to the adverse effect of imatinib mesylate. Molecular oncology, 2008, Volume: 2, Issue:1 Topics: Adaptor Proteins, Signal Transducing; Benzamides; Gene Expression; Humans; Imatinib Mesylate; Lung Neoplasms; Neoplasm Metastasis; Piperazines; Pyrimidines	2008
Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:2 Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Medical Futility; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Retrospective Studies; Treatment Outcome	2010
Esophageal gastrointestinal stromal tumor with pulmonary and bone metastases. Diagnostic and interventional radiology (Ankara, Turkey), 2010, Volume: 16, Issue:3 Topics: Antineoplastic Agents; Benzamides; Bone Neoplasms; Esophageal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Tomography, X-Ray Computed	2010
Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. British journal of cancer, 2010, Apr-13, Volume: 102, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Female; Humans; Imatinib Mesylate; Melanoma; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Skin Neoplasms; Sorafenib	2010
Schedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:2 Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Antagonism; Drug Synergism; Drug Therapy, Combination; Etoposide; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Male; Mitoxantrone; Neoplasm Metastasis; Piperazines; Prostatic Neoplasms; Pyrimidines; Vinblastine	2011
Platelet-derived growth factor receptor beta inhibition increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitivity: imatinib and TRAIL dual therapy. Cancer, 2010, Aug-15, Volume: 116, Issue:16 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Imatinib Mesylate; Mice; Mice, Nude; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Sarcoma, Ewing; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured	2010
Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment. Journal of surgical oncology, 2010, Nov-01, Volume: 102, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease Progression; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome	2010
[Complete response achieved in a case of gastric gastrointestinal stromal tumor by administration of imatinib mesilate with concurrent relatively high-dose steroid therapy to control side effects]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:11 Topics: Benzamides; Drug Eruptions; Drug Therapy, Combination; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Prednisolone; Pruritus; Pyrimidines; Treatment Outcome	2010
Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib. International journal of cancer, 2011, Oct-01, Volume: 129, Issue:7 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Female; Fibrosarcoma; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor beta; Retrospective Studies	2011
Cyclooxygenase-2 expression in gastrointestinal stromal tumours. Asian Pacific journal of cancer prevention : APJCP, 2010, Volume: 11, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chi-Square Distribution; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Progression; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Indoles; Male; Middle Aged; Mitosis; Neoplasm Metastasis; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Tumor Burden	2010
Mutational spectrum and therapy response of metastasized GIST in Central Switzerland - a population-based study. European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Base Sequence; Benzamides; Disease Progression; DNA Mutational Analysis; DNA Primers; Exons; Female; Gastrointestinal Stromal Tumors; Genetics, Population; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Sequence Data; Mutation; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Switzerland	2011
Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model. International journal of cancer, 2011, May-01, Volume: 128, Issue:9 Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blotting, Western; Camptothecin; Cell Proliferation; Fluorescent Antibody Technique; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Irinotecan; Male; Mice; Mice, Nude; Microscopy, Confocal; Neoplasm Metastasis; Neovascularization, Pathologic; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Xenograft Model Antitumor Assays	2011
Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors. International journal of clinical oncology, 2011, Volume: 16, Issue:6 Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Radiography; Sunitinib	2011
β-arrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression. Oncogene, 2012, Jan-19, Volume: 31, Issue:3 Topics: Active Transport, Cell Nucleus; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imatinib Mesylate; Mice; Mice, Nude; Neoplasm Metastasis; Piperazines; Protein Stability; Pyrimidines; Thalidomide; Transcription, Genetic; Vascular Endothelial Growth Factor A	2012
Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer, 2012, Mar-15, Volume: 118, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Fluorodeoxyglucose F18; Giant Cell Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Receptor, Macrophage Colony-Stimulating Factor; Retrospective Studies; Synovitis, Pigmented Villonodular	2012
[Advanced dermatofibrosarcoma protuberans treated with imatinib mesylate]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2011, Volume: 33, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Edema; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Remission Induction; Skin Neoplasms; Survival Rate; Vomiting	2011
Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Nov-20, Volume: 29, Issue:33 Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Thymoma; Thymus Neoplasms	2011
[Twenty-one-year survival case of rectal GIST treated with combined therapies]. Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:12 Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Pyrroles; Rectal Neoplasms; Recurrence; Sunitinib; Time Factors	2011
Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer cell, 2012, Jan-17, Volume: 21, Issue:1 Topics: Animals; Antineoplastic Agents; Benzamides; Benzenesulfonates; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Crizotinib; Epithelial-Mesenchymal Transition; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imatinib Mesylate; Indoles; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Neoplasm Metastasis; Niacinamide; Pericytes; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Tumor Cells, Cultured	2012
Updates on the management of gastrointestinal stromal tumors. Surgical oncology clinics of North America, 2012, Volume: 21, Issue:2 Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pedigree; Piperazines; Pyrimidines; Radiotherapy, Adjuvant; Receptor, Platelet-Derived Growth Factor alpha; Risk Assessment	2012
Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. The Journal of pathology, 2012, Volume: 227, Issue:4 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Imatinib Mesylate; In Vitro Techniques; Indoles; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A	2012
Role of operative therapy in treatment of metastatic gastrointestinal stromal tumors. The Journal of surgical research, 2012, Volume: 177, Issue:2 Topics: Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Minnesota; Neoplasm Metastasis; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib	2012
Patterns of extension of gastrointestinal stromal tumors (GIST) treated with imatinib (Gleevec®) by 18F-FDG PET/CT. Revista espanola de enfermedades digestivas, 2012, Volume: 104, Issue:7 Topics: Aged; Antineoplastic Agents; Benzamides; Drug Monitoring; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome	2012
Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib. Annals of surgical oncology, 2013, Volume: 20, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prognosis; Prospective Studies; Pyrimidines; Rectal Neoplasms; Survival Rate	2013
From chemotherapy to targeted treatment. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23 Suppl 10 Topics: Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Indoles; Melanoma; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Mutation; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms; Sulfonamides; Vemurafenib	2012
The pro-metastasis tyrosine phosphatase, PRL-3 (PTP4A3), is a novel mediator of oncogenic function of BCR-ABL in human chronic myeloid leukemia. Molecular cancer, 2012, Sep-21, Volume: 11 Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression; Gene Expression Regulation, Leukemic; Gene Silencing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Metastasis; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Protein Tyrosine Phosphatases; Pyrimidines; Signal Transduction; STAT Transcription Factors	2012
Tumor volume as an alternative response measurement for imatinib treated GIST patients. PloS one, 2012, Volume: 7, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Automation; Benzamides; Cohort Studies; Disease Progression; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imaging, Three-Dimensional; Imatinib Mesylate; Male; Medical Oncology; Middle Aged; Neoplasm Metastasis; Observer Variation; Piperazines; Pyrimidines; Time Factors; Tomography, X-Ray Computed; Treatment Outcome	2012
KIT (CD117) expression in a subset of non-small cell lung carcinoma (NSCLC) patients. PloS one, 2012, Volume: 7, Issue:12 Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cell Proliferation; Cells, Cultured; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Tumor Cells, Cultured	2012
[A case of multiple metastatic giant rectal GIST successfully treated with surgical intervention after administration of imatinib mesylate]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2013, Volume: 110, Issue:1 Topics: Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Metastasis; Piperazines; Pyrimidines; Rectal Neoplasms	2013
Is exon mutation analysis needed for adjuvant treatment of gastrointestinal stromal tumor? World journal of gastroenterology, 2013, Jan-07, Volume: 19, Issue:1 Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; DNA Mutational Analysis; Exons; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome	2013
Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors. Digestion, 2013, Volume: 87, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome	2013
Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Oct-15, Volume: 9, Issue:13 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Central Nervous System Neoplasms; Chromatography, High Pressure Liquid; Clinical Trials as Topic; DNA Mutational Analysis; Female; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Metastasis; Phenotype; Piperazines; Prognosis; Pyrimidines; Risk; Risk Factors; Time Factors; Treatment Outcome	2003
Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Dec-15, Volume: 9, Issue:17 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Becaplermin; Benzamides; Blotting, Western; Carcinoma; Cell Division; Cell Line, Tumor; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Ligands; Mice; Mice, Nude; Microscopy, Fluorescence; Neoplasm Metastasis; Pancreatic Neoplasms; Phosphorylation; Piperazines; Platelet Endothelial Cell Adhesion Molecule-1; Platelet-Derived Growth Factor; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins c-sis; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor; Time Factors	2003
Isolated abdominal wound metastasis from a gastrointestinal stromal tumor. International journal of gastrointestinal cancer, 2003, Volume: 33, Issue:2-3 Topics: Abdominal Wall; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Digestive System Surgical Procedures; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Laparoscopy; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Postoperative Complications; Pyrimidines; Stromal Cells; Surgical Wound Dehiscence	2003
Molecular response of gastrointestinal stromal tumour after treatment with tyrosine kinase inhibitor imatinib mesylate. Journal of clinical pathology, 2004, Volume: 57, Issue:2 Topics: Adult; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Neoplasm Metastasis; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Stromal Cells; Treatment Outcome	2004
Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, May-15, Volume: 10, Issue:10 Topics: Animals; Antineoplastic Agents; Benzamides; Brain Neoplasms; Carcinoma, Small Cell; Cell Line, Tumor; Humans; Imatinib Mesylate; Immunoblotting; Immunoprecipitation; Ligands; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; NIH 3T3 Cells; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Stem Cell Factor; Time Factors; Tyrosine	2004
Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jan-01, Volume: 11, Issue:1 Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Endothelial Cells; Female; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Nude; Microcirculation; Microscopy, Fluorescence; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Piperazines; Platelet Endothelial Cell Adhesion Molecule-1; Platelet-Derived Growth Factor; Pyrimidines; Radiography; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Time Factors	2005
Lack of response of a metastatic renal perivascular epithelial cell tumor (PEComa) to successive courses of DTIC based-therapy and imatinib mesylate. Pediatric blood & cancer, 2005, Volume: 45, Issue:2 Topics: Angiomyolipoma; Antineoplastic Agents; Benzamides; Child; Dacarbazine; Epithelioid Cells; Fatal Outcome; Female; Humans; Imatinib Mesylate; Kidney Neoplasms; Neoplasm Metastasis; Piperazines; Pyrimidines; Treatment Failure	2005
The role of alpha-interferon in chronic myelogenous leukaemia in Imatinib era. Journal of experimental & clinical cancer research : CR, 2004, Volume: 23, Issue:4 Topics: Aged; Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm Metastasis; Piperazines; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Treatment Outcome	2004
Pathological changes related to Imatinib treatment in a patient with a metastatic gastrointestinal stromal tumour. Histopathology, 2005, Volume: 46, Issue:4 Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome	2005
Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. The Lancet. Oncology, 2005, Volume: 6, Issue:4 Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines	2005
An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients. Melanoma research, 2005, Volume: 15, Issue:4 Topics: Abdominal Neoplasms; Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Spinal Neoplasms; Treatment Outcome	2005
Primary gastrointestinal stromal tumor of the liver with lung metastases successfully treated with STI-571 (imatinib mesylate). Frontiers in bioscience : a journal and virtual library, 2006, Jan-01, Volume: 11 Topics: Adult; Antineoplastic Agents; Benzamides; Cell Differentiation; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Neoplasm Metastasis; Phenotype; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrimidines; Tissue Distribution; Tomography, X-Ray Computed; Treatment Outcome; Vimentin	2006
Complete remission with imatinib in metastastic gastrointestinal stromal tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Sep-20, Volume: 23, Issue:27 Topics: Benzamides; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Pyrimidines; Treatment Outcome	2005
Current management of metastatic gastrointestinal stromal tumor: a case report. Clinical advances in hematology & oncology : H&O, 2003, Volume: 1, Issue:1 Topics: Benzamides; Disease Management; Disease-Free Survival; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines	2003
Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Dec-15, Volume: 11, Issue:24 Pt 1 Topics: Animals; Benzamides; Carcinoma, Hepatocellular; Cell Proliferation; Endothelium, Vascular; Gene Expression Profiling; Humans; Imatinib Mesylate; Interferon-alpha; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Neovascularization, Pathologic; Oligonucleotide Array Sequence Analysis; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Transcriptional Activation	2005
Autocrine PDGFR signaling promotes mammary cancer metastasis. The Journal of clinical investigation, 2006, Volume: 116, Issue:6 Topics: Animals; Antineoplastic Agents; Apoptosis; Autocrine Communication; Benzamides; Breast Neoplasms; Cell Differentiation; Cell Line, Tumor; Enzyme Activation; Epithelial Cells; Female; Humans; Imatinib Mesylate; Mammary Neoplasms, Experimental; Mammary Tumor Virus, Mouse; Mesoderm; Mice; Mice, Nude; Mice, Transgenic; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Piperazines; Protein Kinase Inhibitors; Pyrimidines; ras Proteins; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Recombinant Fusion Proteins; Signal Transduction; Transforming Growth Factor beta	2006
Antivascular therapy of cancer metastasis. Journal of surgical oncology, 2006, Sep-01, Volume: 94, Issue:3 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Disease Progression; Growth Substances; Humans; Imatinib Mesylate; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasms; Paclitaxel; Piperazines; Platelet-Derived Growth Factor; Prostatic Neoplasms; Pyrimidines; Receptors, Growth Factor; Receptors, Platelet-Derived Growth Factor	2006
Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation. Oncogene, 2006, Dec-07, Volume: 25, Issue:58 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Caspases; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Gene Expression Profiling; Humans; Imatinib Mesylate; Melanoma; Neoplasm Metastasis; Oligonucleotide Array Sequence Analysis; Piperazines; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand	2006
Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp. Anti-cancer drugs, 2006, Volume: 17, Issue:10 Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Positron-Emission Tomography; Pyrimidines; Scalp; Skin Neoplasms; Tomography, X-Ray Computed	2006
EORTC-NCI-AACR - 18th Symposium - Molecular Targets and Cancer Therapeutics. Pediatric drugs, biomarkers and new therapies. IDrugs : the investigational drugs journal, 2007, Volume: 10, Issue:1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Child; Drug Design; Humans; Imatinib Mesylate; Neoplasm Metastasis; Neoplasms; Piperazines; Pyrimidines	2007
Is rectal administration an alternative route for imatinib? Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:4 Topics: Administration, Rectal; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Obstruction; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines	2007
Disease progression following imatinib failure in gastrointestinal stromal tumors: role of surgical therapy. The oncologist, 2007, Volume: 12, Issue:4 Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Fatal Outcome; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Tomography, X-Ray Computed	2007
Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13 Topics: Antineoplastic Agents; Benzamides; Disease Progression; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Multivariate Analysis; Neoplasm Metastasis; Piperazines; Positron-Emission Tomography; Protein-Tyrosine Kinases; Pyrimidines; Sensitivity and Specificity; Tomography, X-Ray Computed	2007
We should desist using RECIST, at least in GIST. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13 Topics: Antineoplastic Agents; Benzamides; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Piperazines; Pyrimidines; Recurrence; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome	2007
Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy. International journal of clinical oncology, 2007, Volume: 12, Issue:3 Topics: Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Retrospective Studies; Survival Analysis	2007
Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors. Laboratory investigation; a journal of technical methods and pathology, 2007, Volume: 87, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Exons; Female; Gastrointestinal Stromal Tumors; Homozygote; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Loss of Heterozygosity; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Risk Assessment	2007
Assessment of gastrointestinal stromal tumors with computed tomography following treatment with imatinib mesylate. World journal of gastroenterology, 2008, Feb-14, Volume: 14, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease Progression; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome	2008
Imatinib mesylate treatment for advanced gastrointestinal stromal tumor: a pilot study focusing on patients experiencing sole liver metastasis after a prior radical resection. Oncology, 2007, Volume: 73, Issue:5-6 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pilot Projects; Piperazines; Postoperative Complications; Pyrimidines	2007